Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjustable Brodalumab Dosage Regimen in Psoriasis Patients ≥120 kg
NCT04306315Phase 4Completed
- Sponsor
- LEO Pharma
- Start
- Jul 2022
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 4 trial of brodalumab in plaque psoriasis, sponsored by LEO Pharma. Started Jul 2022; status: completed.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04306315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04306315.